106 related articles for article (PubMed ID: 24820241)
1. Immunotherapy-induced leukoderma from treatment of melanoma with IL-2: a case report and a review of the literature.
Gathings R; Lewallen R; Yosipovitch G
Acta Derm Venereol; 2015 Feb; 95(2):197-200. PubMed ID: 24820241
[TBL] [Abstract][Full Text] [Related]
2. Primary Cutaneous Small/Medium CD4+ T-CELL Lymphoproliferative Disorder Occurring in a Patient With Metastatic Melanoma.
Davick JJ; Gaughan E; Barry M; Gru AA
Am J Dermatopathol; 2018 Jan; 40(1):60-63. PubMed ID: 28719434
[TBL] [Abstract][Full Text] [Related]
3. More support for the judicious use of high-dose interleukin-2 in patients with advanced melanoma.
McDermott DF; Atkins MB
J Clin Oncol; 2007 Sep; 25(25):3791-3. PubMed ID: 17761967
[No Abstract] [Full Text] [Related]
4. Radiation-induced melanoma-associated leucoderma, systemic antimelanoma immunity and disease-free survival in a patient with advanced-stage melanoma: a case report and immunological analysis.
Teulings HE; Tjin EP; Willemsen KJ; Krebbers G; van Noesel CJ; Kemp EH; Nieuweboer-Krobotova L; van der Veen JP; Luiten RM
Br J Dermatol; 2013 Apr; 168(4):733-8. PubMed ID: 23421690
[TBL] [Abstract][Full Text] [Related]
5. Dynamic changes of specific T cell responses to melanoma correlate with IL-2 administration.
Andersen MH; Gehl J; Reker S; Pedersen LØ; Becker JC; Geertsen P; thor Straten P
Semin Cancer Biol; 2003 Dec; 13(6):449-59. PubMed ID: 15001164
[TBL] [Abstract][Full Text] [Related]
6. High-dose interleukin-2 (IL-2) for the treatment of melanoma: safety considerations and future directions.
Marabondo S; Kaufman HL
Expert Opin Drug Saf; 2017 Dec; 16(12):1347-1357. PubMed ID: 28929820
[TBL] [Abstract][Full Text] [Related]
7. Lack of terminally differentiated tumor-specific CD8+ T cells at tumor site in spite of antitumor immunity to self-antigens in human metastatic melanoma.
Mortarini R; Piris A; Maurichi A; Molla A; Bersani I; Bono A; Bartoli C; Santinami M; Lombardo C; Ravagnani F; Cascinelli N; Parmiani G; Anichini A
Cancer Res; 2003 May; 63(10):2535-45. PubMed ID: 12750277
[TBL] [Abstract][Full Text] [Related]
8. Opportunistic autoimmunity secondary to immunotherapy and melanoma: Back to ABCDE?
Kostine M; Stavris C; Chiche L
Eur J Cancer; 2017 Aug; 81():240-241. PubMed ID: 28434854
[No Abstract] [Full Text] [Related]
9. Treatment for metastatic malignant melanoma: old drugs and new strategies.
Mouawad R; Sebert M; Michels J; Bloch J; Spano JP; Khayat D
Crit Rev Oncol Hematol; 2010 Apr; 74(1):27-39. PubMed ID: 19781957
[TBL] [Abstract][Full Text] [Related]
10. [Malignant melanoma, leukoderma and vitiligo].
Kraus L; Landthaler M
Z Hautkr; 1980 Feb; 55(4):218-31. PubMed ID: 6996365
[TBL] [Abstract][Full Text] [Related]
11. Detailed protocol for administration of intralesional IL-2 for the treatment of Stage IIIc and IV M1a metastatic melanoma based on current NCCN guidelines.
Patel F; Wilken R; Burrall B; Martinez S; Wells V; King B; Maverakis E
Dermatol Online J; 2014 Nov; 20(11):. PubMed ID: 25419744
[TBL] [Abstract][Full Text] [Related]
12. [Treatment of metastasized malignant melanoma].
Kamanabrou D
Praxis (Bern 1994); 2001 Mar; 90(10):391-6. PubMed ID: 11305184
[TBL] [Abstract][Full Text] [Related]
13. Radiologic aspects of immune-related tumor response criteria and patterns of immune-related adverse events in patients undergoing ipilimumab therapy.
O'Regan KN; Jagannathan JP; Ramaiya N; Hodi FS
AJR Am J Roentgenol; 2011 Aug; 197(2):W241-6. PubMed ID: 21785048
[TBL] [Abstract][Full Text] [Related]
14. Vaccination with mRNA-electroporated dendritic cells induces robust tumor antigen-specific CD4+ and CD8+ T cells responses in stage III and IV melanoma patients.
Aarntzen EH; Schreibelt G; Bol K; Lesterhuis WJ; Croockewit AJ; de Wilt JH; van Rossum MM; Blokx WA; Jacobs JF; Duiveman-de Boer T; Schuurhuis DH; Mus R; Thielemans K; de Vries IJ; Figdor CG; Punt CJ; Adema GJ
Clin Cancer Res; 2012 Oct; 18(19):5460-70. PubMed ID: 22896657
[TBL] [Abstract][Full Text] [Related]
15. CTLA4-induced splenomegaly and a review of the literature pertaining to autoimmune complications of therapy.
Ezra N; Goltche NB; Hakimian S; Afari A
J Drugs Dermatol; 2010 Nov; 9(11):1432-6. PubMed ID: 21061768
[TBL] [Abstract][Full Text] [Related]
16. Functional up-regulation of human leukocyte antigen class I antigens expression by 5-aza-2'-deoxycytidine in cutaneous melanoma: immunotherapeutic implications.
Fonsatti E; Nicolay HJ; Sigalotti L; Calabrò L; Pezzani L; Colizzi F; Altomonte M; Guidoboni M; Marincola FM; Maio M
Clin Cancer Res; 2007 Jun; 13(11):3333-8. PubMed ID: 17545540
[TBL] [Abstract][Full Text] [Related]
17. Phase I trial of combined immunotherapy with subcutaneous granulocyte macrophage colony-stimulating factor, low-dose interleukin 2, and interferon alpha in progressive metastatic melanoma and renal cell carcinoma.
de Gast GC; Klümpen HJ; Vyth-Dreese FA; Kersten MJ; Verra NC; Sein J; Batchelor D; Nooijen WJ; Schornagel JH
Clin Cancer Res; 2000 Apr; 6(4):1267-72. PubMed ID: 10778950
[TBL] [Abstract][Full Text] [Related]
18. [Are immunological treatments beneficial for malignant melanoma of the skin?].
Vihinen P; Vuoristo MS; Hernberg M; Pyrhönen S
Duodecim; 2010; 126(14):1701-10. PubMed ID: 20804089
[TBL] [Abstract][Full Text] [Related]
19. Treatment and side effect management of CTLA-4 antibody therapy in metastatic melanoma.
Kähler KC; Hauschild A
J Dtsch Dermatol Ges; 2011 Apr; 9(4):277-86. PubMed ID: 21083648
[TBL] [Abstract][Full Text] [Related]
20. Vitiligo in patients with melanoma: normal tissue antigens can be targets for cancer immunotherapy.
Rosenberg SA; White DE
J Immunother Emphasis Tumor Immunol; 1996 Jan; 19(1):81-4. PubMed ID: 8859727
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]